IgA nephropathy (IgAN) is the most common form of glomerulonephritis, an inflammatory disease of the kidney. IgAN is characterized by deposition of lgA1 antibodies in the glomerular mesangium of the kidney, followed by infiltration of inflammatory immune cells and eventual loss of kidney function. lgA1 antibodies show altered glycosylation and polymerization states in a large percentage of IgAN patients. These alterations have been suggested to play a role in modifying the interactions between lgA1 and IgA-specific receptors, particularly, FcalphaRI (CD89) and transferrin receptor (TfR), although conflicting data have been reported. The long-term goal of this research effort is to ascertain the precise molecular events that lead to lgA1 deposition in the mesangium. The central hypothesis is that modifications in lgA1 glycosylation and polymerization lead to increased affinity for critical IgA-binding receptors (specifically, FcalphaRI and TfR). These aberrant interactions are proposed to lead directly to deposition of lgA1 in the kidney mesangium and the ensuing inflammatory response.
Specific Aims for this proposal include: 1) Characterize the effects of lgA1 glycosylation and polymerization on its interaction with FcalphaRI and TfR, using recombinant lgA1 with defined glycosylation states;2) Characterize the receptor interactions of lgA1 purified from serum of healthy and IgAN patients and correlate the receptor affinity with lgA1 glycosylation and polymerization state;and 3) Determine the contribution of FcalphaRI N-glycosylation to its interaction with lgA1 and TfR. Binding studies with lgA1, FcalphaRI, and TfR will be carried out by surface plasmon resonance and analytical ultracentrifugation. lgA1 glycosylation will be characterized by lectin affinity assays along with thorough analysis of samples of interest by Fourier transform-ion cyclotron resonance mass spectrometry. This research will help determine the molecular basis for IgA nephropathy (IgAN), a kidney disease affecting approximately 100,000 patients in the US. IgAN is a primary cause of end-stage renal disease, which costs $18 billion per year in medical care. Understanding the molecular interactions underlying IgAN will be the first step towards developing treatments for this costly and debilitating disease.
| Posgai, Monica T; Tonddast-Navaei, Sam; Jayasinghe, Manori et al. (2018) Fc?RI binding at the IgA1 CH2-CH3 interface induces long-range conformational changes that are transmitted to the hinge region. Proc Natl Acad Sci U S A 115:E8882-E8891 |
| Eison, T Matthew; Hastings, M Colleen; Moldoveanu, Zina et al. (2012) Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy. Clin Nephrol 78:465-9 |
| Novak, Jan; Julian, Bruce A; Mestecky, Jiri et al. (2012) Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 34:365-82 |
| Takahashi, Kazuo; Smith, Archer D; Poulsen, Knud et al. (2012) Naturally occurring structural isomers in serum IgA1 o-glycosylation. J Proteome Res 11:692-702 |
| Novak, Jan; Moldoveanu, Zina; Julian, Bruce A et al. (2011) Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol 72:60-3 |
| Novak, Jan; Raskova Kafkova, Leona; Suzuki, Hitoshi et al. (2011) IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant 26:3451-7 |
| Camilla, Roberta; Suzuki, Hitoshi; Daprà , Valentina et al. (2011) Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6:1903-11 |
| Lindfors, Katri; Suzuki, Hitoshi; Novak, Jan et al. (2011) Galactosylation of serum IgA1 O-glycans in celiac disease. J Clin Immunol 31:74-9 |
| Suzuki, Hitoshi; Kiryluk, Krzysztof; Novak, Jan et al. (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795-803 |
| He, Mei; Novak, Jan; Julian, Bruce A et al. (2011) Membrane-assisted online renaturation for automated microfluidic lectin blotting. J Am Chem Soc 133:19610-3 |
Showing the most recent 10 out of 42 publications
